Published by FirstAlign
Do you know how much time it takes to develop a new drug? Three, four, or maybe five years. No! Ten years! Yes, it takes ten years to create, build, and certify a new drug. An average of 6 years for clinical research alone. No wonder a vaccine for Covid19 is taking so long.
The time taken may seem daunting, but the rigorous R&D process requires significant effort to get a drug to a patient. With so many advanced technologies around us, isn’t there a solution to speed things up? Can’t we use Artificial Intelligence to enhance the process? What is the future of chemical research?
IBM answers our questions with RoboRXN.
What is RoboRXN?
The process from research to development is a difficult and lengthy one. On average clinical trials alone take six to seven years. The average cost from research to developing a successful drug is estimated to be $2.6 billion.
In 2018, IBM developed Machine Learning models to predict chemical reactions. They called it RXN Chemistry. The service was launched free via IBM Cloud.
RXN Chemistry used the state-of-the-art neural machine learning translation method. This method can predict the most likely outcome of a chemical reaction. It uses neural machine translation architectures, a process that is similar to translating languages. RXN chemistry translates the language of chemistry, converting reactants and reagents to products. Even today, RXN Chemistry is a unique data-driven Artificial Intelligence method for reaction prediction with more than 90% accuracy.
RoboRXN is the latest and advanced version of RXN Chemistry. IBM has integrated a retrosynthetic architecture into the RXN tool. Retrosynthetic is a well-known process in chemistry that determines the chemicals needed to create a target molecule.
RoboRXN is a combination of AI, cloud technology, and chemistry automation. It is purely machine learning algorithms designing and executing molecules from a remote laboratory (Cloud) with little human intervention.
RoboRXN is entirely data-driven, and the entire set of services are implemented on the IBM cloud for easy accessibility from around the world.
How RoboRXN works?
RoboRXN works through a web browser. You can connect and use the blank canvas to type and draw the molecular compound’s required structure. RoboRXN uses ML algorithms to predict the components needed and the right steps of the chemical procedure. It then converts this information into a machine-readable format. The converted information is sent to a robot placed in an independent lab to execute the formula. RoboRXN sends real-time reports to the scientist with the results.
Future of chemical research
RoboRXN- a combination of AI, cloud, and automation, is changing the future of chemical research. It relieves scientists from performing those repetitive, tedious tasks. They can now use their time in design and analysis. In turn, this promises to reduce the time taken for making a new drug and bring down the costs in the process.
As IBM takes its first step in changing the chemical research industry, we can soon see many more startups working towards solving similar problems.
Imagine how RoboRXN can bring down the discovery period of a new treatment for COVID 19 by half—saving time, money, and lives. The future of chemical research with AI looks promising as it aids humans in building a better tomorrow.
Know more about us:
You might also be interested to follow FirstAlign to get the latest updates https://www.linkedin.com/company/firstalign
- @technologyreview: IBM has built a new drug-making lab entirely in the cloud
- @ibm: RoboRXN: Automating Chemical Synthesis
- @bdtechtalks: How artificial intelligence and robotics are changing chemical research
- @techgenyz: IBM introduces cloud-based AI platform RoboRXN to accelerate drug synthesis
- @hyperaxion: RoboRXN: IBM’s drug-making lab powered by AI and cloud technology
- @chemistryworld: IBM seeks to simplify robotic chemistry
- @dailyalts: Artificial Intelligence: About RoboRXN, IBM’s Lab In The Cloud
- @spectrum: Robotics, AI, and Cloud Computing Combine to Supercharge Chemical and Drug Synthesis
Published by FirstAlign